Amgen threatens to steal show at ASCO 2019 with KRAS data

3 June 2019

Deciding which company has presented the most significant data at an ASCO meeting is often a matter of perspective, but Amgen (Nasdaq: AMGN) is definitely a contender at this year's event.

The US biotech’s share price was up 4% after the morning’s trading on Monday, when it presented the first results from its Phase I study investigating AMG 510, the first KRASG12C inhibitor to reach the clinical stage.

"KRAS has been a target of active exploration in cancer research since it was identified as one of the first oncogenes more than 30 years ago"In the trial, 35 patients were enrolled with various tumor types, and out of 10 with non-small cell lung cancer, five experienced a partial response (PR), and another four had stable disease. One patient with PR improved further to a complete response of the target lesions at week 18, post data cut-off.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK